Zentek (ZTEK)
Market Price (1/22/2026): $0.814 | Market Cap: $85.2 MilSector: Health Care | Industry: Health Care Equipment
Zentek (ZTEK)
Market Price (1/22/2026): $0.814Market Cap: $85.2 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2226% | Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -115% | Penny stockMkt Price is 0.8 |
| Megatrend and thematic driversMegatrends include Advanced Materials, and Battery Technology & Metals. Themes include Nanomaterials, Specialty Chemicals for Performance, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -965% | |
| Expensive valuation multiplesP/SPrice/Sales ratio is 93x | ||
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -60% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 80% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -592%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -647% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% | ||
| Key risksZTEK key risks include [1] severe financial instability and going concern uncertainty due to minimal revenue and substantial losses, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2226% |
| Megatrend and thematic driversMegatrends include Advanced Materials, and Battery Technology & Metals. Themes include Nanomaterials, Specialty Chemicals for Performance, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -115% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -965% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 93x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -60% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 80% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -592%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -647% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% |
| Key risksZTEK key risks include [1] severe financial instability and going concern uncertainty due to minimal revenue and substantial losses, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Zentek (ZTEK) stock has gained about 5% since 9/30/2025 because of the following key factors:
1. Advancements in Albany Graphite's Performance for Nuclear and Battery Markets. Zentek's stock gained due to significant developments with its Albany Graphite, including positive nuclear suitability testing results reported on October 6, 2025, and further demonstration of nuclear-grade performance on January 5, 2026, which opened pathways into high-return commercial markets. Additionally, the Albany Graphite subsidiary achieved near-theoretical anode performance in independent battery suitability testing on December 17, 2025, indicating strong potential in the energy storage sector.
2. Development and Commercialization of a New Fire-Retardant Product. The company announced the development of a new graphite gel-based fire-retardant product and secured an exclusive license with Altek Advanced Materials Inc. for the US market on November 5, 2025, diversifying its product portfolio and establishing a commercialization path for this innovation.
Show more
1. Advancements in Albany Graphite's Performance for Nuclear and Battery Markets. Zentek's stock gained due to significant developments with its Albany Graphite, including positive nuclear suitability testing results reported on October 6, 2025, and further demonstration of nuclear-grade performance on January 5, 2026, which opened pathways into high-return commercial markets. Additionally, the Albany Graphite subsidiary achieved near-theoretical anode performance in independent battery suitability testing on December 17, 2025, indicating strong potential in the energy storage sector.
2. Development and Commercialization of a New Fire-Retardant Product. The company announced the development of a new graphite gel-based fire-retardant product and secured an exclusive license with Altek Advanced Materials Inc. for the US market on November 5, 2025, diversifying its product portfolio and establishing a commercialization path for this innovation.
Show more
Stock Movement Drivers
Fundamental Drivers
The -1.3% change in ZTEK stock from 10/31/2025 to 1/21/2026 was primarily driven by a -1.0% change in the company's Total Revenues ($ Mil).| 10312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 0.82 | 0.81 | -1.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1 | 1 | -1.0% |
| P/S Multiple | 93.3 | 93.1 | -0.2% |
| Shares Outstanding (Mil) | 105 | 105 | -0.1% |
| Cumulative Contribution | -1.3% |
Market Drivers
10/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| ZTEK | -1.3% | |
| Market (SPY) | 0.5% | 23.7% |
| Sector (XLV) | 9.7% | -0.4% |
Fundamental Drivers
The -7.8% change in ZTEK stock from 7/31/2025 to 1/21/2026 was primarily driven by a -11.7% change in the company's P/S Multiple.| 7312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 0.88 | 0.81 | -7.8% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1 | 1 | 4.9% |
| P/S Multiple | 105.5 | 93.1 | -11.7% |
| Shares Outstanding (Mil) | 104 | 105 | -0.5% |
| Cumulative Contribution | -7.8% |
Market Drivers
7/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| ZTEK | -7.8% | |
| Market (SPY) | 8.7% | 12.1% |
| Sector (XLV) | 21.9% | 2.2% |
Fundamental Drivers
The -27.3% change in ZTEK stock from 1/31/2025 to 1/21/2026 was primarily driven by a -96.8% change in the company's P/S Multiple.| 1312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.12 | 0.81 | -27.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0 | 1 | 2225.7% |
| P/S Multiple | 2,921.8 | 93.1 | -96.8% |
| Shares Outstanding (Mil) | 103 | 105 | -2.0% |
| Cumulative Contribution | -27.4% |
Market Drivers
1/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| ZTEK | -27.3% | |
| Market (SPY) | 14.9% | 16.4% |
| Sector (XLV) | 9.2% | 14.6% |
Fundamental Drivers
The -43.9% change in ZTEK stock from 1/31/2023 to 1/21/2026 was primarily driven by a -85.6% change in the company's P/S Multiple.| 1312023 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.45 | 0.81 | -43.9% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0 | 1 | 311.1% |
| P/S Multiple | 647.3 | 93.1 | -85.6% |
| Shares Outstanding (Mil) | 99 | 105 | -5.4% |
| Cumulative Contribution | -44.0% |
Market Drivers
1/31/2023 to 1/21/2026| Return | Correlation | |
|---|---|---|
| ZTEK | -43.9% | |
| Market (SPY) | 74.9% | 11.8% |
| Sector (XLV) | 24.2% | 9.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ZTEK Return | 0% | 534% | -30% | -13% | -32% | 29% | 238% |
| Peers Return | 14% | 33% | -20% | -1% | -30% | 35% | 15% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| ZTEK Win Rate | 0% | 25% | 33% | 33% | 42% | 100% | |
| Peers Win Rate | 50% | 58% | 33% | 33% | 42% | 100% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 0% | |
Max Drawdowns [4] | |||||||
| ZTEK Max Drawdown | 0% | 0% | -33% | -50% | -32% | 0% | |
| Peers Max Drawdown | 0% | -10% | -26% | -37% | -43% | 0% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CVV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/21/2026 (YTD)
How Low Can It Go
| Event | ZTEK | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -69.4% | -25.4% |
| % Gain to Breakeven | 226.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.1% | -33.9% |
| % Gain to Breakeven | 113.4% | 51.3% |
| Time to Breakeven | 722 days | 148 days |
Compare to CVV
In The Past
Zentek's stock fell -69.4% during the 2022 Inflation Shock from a high on 3/23/2022. A -69.4% loss requires a 226.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
N/A
AI Analysis | Feedback
Like **3M**, but focused on next-generation graphene-based materials for applications in healthcare, defense, and water solutions.
A specialized **DuPont** for cutting-edge graphene and advanced materials, serving sectors such as healthcare and defense.
AI Analysis | Feedback
Here are Zentek's major products and services:
- ZenGUARDâ„¢ Technology: A graphene-based antimicrobial coating primarily used for personal protective equipment, HVAC systems, and other surfaces to inhibit microbial growth.
- Graphene-based Battery Materials: Advanced materials, often incorporating silver-graphene composites, designed to enhance the performance and efficiency of battery technologies, particularly solid-state batteries.
- Specialty Graphene Coatings: A range of graphene-enhanced coatings developed for industrial applications, including icephobic (anti-icing) and corrosion protection solutions.
- Detectâ„¢ Rapid Diagnostic Platform: A point-of-care diagnostic platform leveraging graphene for the rapid and accurate detection of various pathogens.
AI Analysis | Feedback
Zentek (ZTEK) primarily operates on a Business-to-Business (B2B) model, selling its nanotechnology-based products and materials to other companies for integration into their own products or for use in their operations.
Its major identified customers or significant partners include:
- Trebor Health Protection Inc. (formerly Trebor Rx Corp.): Zentek has a supply agreement with Trebor for its ZenGUARDâ„¢ antimicrobial coating, which Trebor integrates into personal protective equipment (PPE) such as masks. Trebor Rx Corp. was previously a public company (CSE: TREL, OTCQB: TRRXF); however, Trebor Health Protection Inc. does not appear to have a readily identifiable public stock symbol at this time, suggesting it may now operate as a private entity or trade on less prominent exchanges.
- Unnamed Private Companies in HVAC and Other Sectors: Zentek has reported receiving orders for its ZenGUARDâ„¢ antimicrobial HVAC filters from multiple private companies across North America. Additionally, Zentek works with other private companies as distribution partners (e.g., Allied Scientific Pro for graphene materials) and collaborators for various applications (e.g., BMS Aerospace for corrosion protection), whose specific purchasing volumes or public symbols are not disclosed.
AI Analysis | Feedback
- Albemarle Corporation (ALB)
AI Analysis | Feedback
Wendy Ford Interim-Chief Executive Officer and Chief Financial Officer
Wendy Ford has over three decades of experience in finance and accounting leadership roles for both private and publicly traded companies. Most recently, she served as VP of Finance and CFO of Mancor Industries, a precision manufacturer, and prior to that, she was the CFO of AirBoss of America, a publicly traded company. Ford is a Chartered Professional Accountant (CPA) and a graduate of the University of Toronto.
Dr. Francis Dubé Chairman
Dr. Francis Dubé, an optometrist with a science and healthcare background, was a co-founder and director of Cannacure Corp., a private cannabis company that was successfully bought out. He was the first CEO and Chairman of Zentek (then Zenyatta Ventures) after a proxy battle in 2018, playing a crucial role in transforming the company from a graphite mining developer to a graphene intellectual property and product developer.
Dr. Colin van der Kuur Chief Science Officer
Dr. Colin van der Kuur was the first graduate from the University of Guelph with a Specialized Honours in chemical physics and later earned a doctorate in leadership. He spent 25 years in the non-profit sector, training and coaching executives. He joined Zentek in 2018 and has been pivotal in identifying and developing key technologies and securing intellectual property rights for the company.
Ryan Shacklock Senior Vice President, Strategy and Business Development
Ryan Shacklock joined Zentek in 2021. He has successfully managed various responsibilities including business strategy, business development, marketing, investor relations, and government affairs.
Peter Wood VP, Development
Peter Wood is a geological engineer with over 35 years of experience in exploration and project management within the mining industry, having worked with major companies such as Newmont, Homestake, and HudBay. He joined Zentek (then ZEN) in January 2013 as Vice President, Exploration, and was promoted to Vice President and then President in 2018. He is also involved with Albany Graphite Corporation.
AI Analysis | Feedback
The key risks to Zentek (ZTEK) are as follows:- Financial Instability and Going Concern Uncertainty: Zentek faces significant financial challenges, including minimal revenue (less than USD$1 million), declining earnings over the past five years, and an accumulated deficit. The company has reported recurring losses from operations, which raises substantial doubt about its ability to continue as a going concern. This instability is further highlighted by the abysmal sales of its highly promoted ZenGUARD face masks, which generated only $380,000 against $15 million in losses from continuing operations in a recent four-quarter period.
- Intellectual Property Litigation and Allegations of Theft: Zentek is exposed to considerable intellectual property risk due to a lawsuit filed by a former partner. This partner alleges that Zentek stole its graphene-based antimicrobial coating technology (ZenGUARD ink) during a collaboration in 2020. The lawsuit seeks to prevent Zentek from selling the ink, alongside demands for monetary damages and disgorgement of profits, which could severely impact the company's core product offerings and financial viability.
- Challenges in Market Demand and Commercialization: The company has demonstrated difficulties in accurately assessing and capitalizing on market opportunities. Management has severely misjudged the demand for ZenGUARD ink in the surgical face mask market, which has been characterized by waning demand and intense competition. Furthermore, the commercialization of its other developmental technologies, such as disease detection devices, is projected to be several years away, and there is no assurance that the company's research and development will result in profitable operations in the highly risky technology industry. Zentek also faces challenges in converting the technical achievements of its battery materials into commercial traction.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Zentek's main products and services are outlined below:
-
ZenGUARDâ„¢ Antimicrobial Coating (for masks, HVAC filters, PPE, and indoor air quality applications):
- The global antimicrobial coatings market was valued at approximately USD 12.84 billion in 2024 and is projected to reach USD 33.65 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 12.80% during the forecast period. North America held approximately 45% of the global market share in 2024.
- The global indoor air purification market was valued at USD 24,700.4 million in 2024 and is projected to grow at a CAGR of 6.4% from 2025 to 2030.
-
Icephobic Coatings (Ice Graphene):
- The global anti-icing coating market was valued at USD 1.72 billion in 2024 and is expected to grow at a CAGR of 22.65% from 2025 to 2032, reaching nearly USD 8.85 billion. North America dominated the global anti-icing coating market in 2023, generating a revenue of USD 443.9 million and expected to reach around USD 2.9 billion by 2032.
-
ZenARMORâ„¢ (Anti-corrosion coatings):
- The global anticorrosion coatings market size was valued at USD 38.13 billion in 2024. The market is projected to grow from USD 36.72 billion in 2025 to USD 54.35 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period. Asia Pacific dominated this market with a share of 61.34% in 2024. Another estimate values the global corrosion protection coatings and acid-proof lining market at USD 53.1 billion in 2025, expected to reach USD 99.8 billion by 2035, growing at a CAGR of 6.5%.
-
Pathogen Detection Technology (Aptamers & Rapid Detection):
- The global rapid diagnostics market size was estimated at USD 42.32 billion in 2024 and is predicted to increase from USD 51.12 billion in 2025 to approximately USD 280.03 billion by 2034, expanding at a CAGR of 20.80%. North America led the global market with the highest market share of 31% in 2024.
-
Albany Graphite Project (Graphite/Graphene materials):
- The global graphite market size was estimated at USD 31.59 billion in 2025 and is predicted to increase from USD 34.18 billion in 2026 to approximately USD 65.60 billion by 2034, expanding at a CAGR of 8.42% from 2025 to 2034. Asia-Pacific contributed more than 61% of revenue share in 2024.
- The global graphene market size was valued at USD 694.0 million in 2024. The market is projected to grow from USD 941.1 million in 2025 to USD 8,329.9 million by 2032, exhibiting a CAGR of 36.5%.
-
New Graphite Gel-Based Fire-Retardant Product:
- The global fire retardant coatings market is projected to grow from USD 6.1 billion in 2025 to USD 10.9 billion by 2035, at a CAGR of 6.0%. Another report indicates the fire retardant coating market is valued at USD 3.14 billion in 2024, reflecting a strong foundation for future expansion, and is anticipated to reach USD 5.56 billion by 2035, with a compound annual growth rate (CAGR) of 5.33% from 2025 to 2035.
-
Graphene-Wrapped Silicon Anode (for batteries):
- The global silicon anode battery market size was valued at USD 97.97 billion in 2024 and is expected to reach USD 490.34 billion by 2032, at a CAGR of 22.3%. The automotive segment dominated this market in 2024.
- The global graphene battery market size was estimated at USD 215.85 million in 2024 and is predicted to increase from USD 272.68 million in 2025 to approximately USD 2,234.66 million by 2034, expanding at a CAGR of 26.33%. Asia Pacific dominated the global graphene batteries market in 2024.
AI Analysis | Feedback
Zentek (symbol: ZTEK) is anticipated to experience future revenue growth over the next 2-3 years driven by several key initiatives and product advancements:
- Expanded Commercialization and Global Reach of ZenGUARDâ„¢: Zentek is focusing on scaling operations and enhancing its ZenGUARDâ„¢ product line, which includes graphene-based antimicrobial coatings for surgical masks, personal protective equipment (PPE), and HVAC filters. The company has demonstrated the superior performance of its ZenGUARDâ„¢ Enhanced Air Filters and is actively pursuing global expansion through strategic partnerships in regions such as Canada, the Middle East, India, and South America. This initiative aims to meet increasing global demand for advanced healthcare and air quality solutions.
- Introduction and Commercialization of GraphGelâ„¢: A significant driver is the recent development and licensing of GraphGelâ„¢, a novel Graphite Gel-Based Fire-Retardant product. Zentek announced an exclusive agreement with Altek Advanced Materials Inc. to commercialize this technology in the US market, with Altek intending to launch it under the GraphGelâ„¢ brand. This innovative solution has achieved a Class A fire rating, offering a new revenue stream in wildfire protection for homes and other structures.
- Advanced Graphite Materials for High-Purity Applications: Zentek's subsidiary, Albany Graphite Corp., has achieved significant milestones in purifying graphite to an ultra-high 5N purity level (99.9992% C), meeting the stringent requirements for the nuclear industry. This high-purity Albany graphite is also being explored for applications in energy storage and battery materials, positioning the company to capture opportunities in the rapidly expanding advanced materials sector.
- Development and Commercialization of Aptamer-based Technologies: Zentek is progressing with its aptamer platform, evidenced by promising preliminary results from in vivo tests of an influenza countermeasure candidate. Animals treated with the aptamer lead candidate showed significantly higher survival rates and reduced weight loss. The company aims for the growth and commercialization of its aptamer-based technologies, indicating future revenue potential in the biomedical and pharmaceutical sectors.
AI Analysis | Feedback
Share Repurchases
- Zentek repurchased common stock totaling $0.05 million for the fiscal year ended March 31, 2025.
- Common stock repurchases amounted to $0.14 million for the fiscal year ended March 31, 2024.
- For the fiscal year ended March 31, 2023, the company's common stock repurchases were $0.41 million.
- During the three months ended June 30, 2024, Zentek purchased $90,629 in shares for cancellation.
Share Issuance
- In October 2025, Zentek closed a non-brokered private placement, issuing 2,338,893 units for gross proceeds of $2,479,227, which will be used for working capital and general corporate purposes. This offering was initially announced at up to $2.5 million.
- For the fiscal year ended March 31, 2025, gross proceeds from a non-brokered private placement amounted to $3,069,950.
- Proceeds from the issuance of common stock were $3.24 million for the fiscal year ended March 31, 2025, $3.3 million for the fiscal year ended March 31, 2024, and $0.11 million for the fiscal year ended March 31, 2023.
Inbound Investments
- Zentek's subsidiary, Albany Graphite Corp., was awarded a $500,000 grant from Ontario's Critical Minerals Innovation Fund in September 2025, specifically for graphite purification and anode development.
Capital Expenditures
- Capital expenditures were approximately $0.20 million for the fiscal year ended March 31, 2025, $0.18 million for the fiscal year ended March 31, 2024, $0.59 million for the fiscal year ended March 31, 2023, $2.27 million for the fiscal year ended March 31, 2022, and $4.30 million for the fiscal year ended March 31, 2021.
- As of June 30, 2025, approximately $2,490,900 has been spent on the aptamer-based rapid test project.
- As of March 31, 2025, approximately $576,000 had been spent on the ZenGUARDâ„¢ HVAC project since January 1, 2022, focused on developing pathogen-deactivating HVAC filters.
- Mineral exploration and evaluation expenditures capitalized were $53,242 for the three months ended June 30, 2025, and $33,131 for the three months ended June 30, 2024.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can Zentek Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Zentek
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.55 |
| Mkt Cap | 0.1 |
| Rev LTM | 15 |
| Op Inc LTM | -5 |
| FCF LTM | -4 |
| FCF 3Y Avg | -5 |
| CFO LTM | -4 |
| CFO 3Y Avg | -4 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1,122.8% |
| Rev Chg 3Y Avg | 358.1% |
| Rev Chg Q | -35.0% |
| QoQ Delta Rev Chg LTM | -1.9% |
| Op Mgn LTM | -483.4% |
| Op Mgn 3Y Avg | -8,678.3% |
| QoQ Delta Op Mgn LTM | -3.0% |
| CFO/Rev LTM | -299.3% |
| CFO/Rev 3Y Avg | -6,477.2% |
| FCF/Rev LTM | -326.6% |
| FCF/Rev 3Y Avg | -6,903.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Intellectual Property (IP) Development | 0 | ||||
| Albany Project | 0 | ||||
| BioTech | 0 | ||||
| Unallocated Corporate Costs | 0 | ||||
| Other income | 0 | 0 | |||
| Sales | 0 | 0 | |||
| Total | 0 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Albany Project | -1 | ||||
| BioTech | -1 | ||||
| Unallocated Corporate Costs | -2 | ||||
| Intellectual Property (IP) Development | -8 | ||||
| Total | -12 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Intellectual Property (IP) Development | 15 | ||||
| Albany Project | 7 | ||||
| BioTech | 0 | ||||
| Unallocated Corporate Costs | 0 | ||||
| Single segment | 30 | 26 | |||
| Total | 23 | 30 | 26 |
Price Behavior
Price Behavior
| Market Price | $0.81 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 03/30/2012 | |
| Distance from 52W High | -54.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.76 | $0.99 |
| DMA Trend | down | down |
| Distance from DMA | 7.3% | -18.1% |
| 3M | 1YR | |
| Volatility | 78.7% | 87.2% |
| Downside Capture | 237.01 | 128.75 |
| Upside Capture | 208.07 | 80.16 |
| Correlation (SPY) | 26.2% | 15.6% |
ZTEK Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.38 | 1.15 | 1.13 | 0.68 | 0.71 | 0.54 |
| Up Beta | 5.82 | 0.54 | 0.74 | 0.73 | 0.65 | 0.50 |
| Down Beta | -1.05 | 2.01 | 0.69 | 0.15 | 0.68 | 0.83 |
| Up Capture | -157% | -15% | 76% | 0% | 37% | 5% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 14 | 23 | 45 | 95 | 299 |
| Down Capture | 190% | 185% | 175% | 172% | 104% | 87% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 13 | 26 | 40 | 77 | 144 | 409 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZTEK | |
|---|---|---|---|---|
| ZTEK | -33.6% | 87.4% | -0.11 | - |
| Sector ETF (XLV) | 14.5% | 17.4% | 0.62 | 12.8% |
| Equity (SPY) | 15.8% | 19.3% | 0.63 | 15.7% |
| Gold (GLD) | 79.5% | 20.4% | 2.78 | 8.8% |
| Commodities (DBC) | 5.7% | 15.3% | 0.16 | 12.1% |
| Real Estate (VNQ) | 5.8% | 16.7% | 0.17 | 8.0% |
| Bitcoin (BTCUSD) | -14.7% | 39.8% | -0.31 | 16.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZTEK | |
|---|---|---|---|---|
| ZTEK | -27.8% | 75.6% | -0.12 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 12.5% |
| Equity (SPY) | 14.0% | 17.1% | 0.66 | 15.5% |
| Gold (GLD) | 20.8% | 15.7% | 1.07 | 9.7% |
| Commodities (DBC) | 11.4% | 18.7% | 0.49 | 8.3% |
| Real Estate (VNQ) | 5.7% | 18.8% | 0.21 | 13.1% |
| Bitcoin (BTCUSD) | 19.0% | 58.0% | 0.53 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZTEK | |
|---|---|---|---|---|
| ZTEK | -15.3% | 76.9% | -0.07 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 11.9% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 15.4% |
| Gold (GLD) | 15.7% | 14.9% | 0.87 | 8.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 11.7% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 12.8% |
| Bitcoin (BTCUSD) | 70.3% | 66.7% | 1.09 | 18.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 6-K (09/30/2025) |
| 06/30/2025 | 08/14/2025 | 6-K (06/30/2025) |
| 03/31/2025 | 06/27/2025 | 40-F (03/31/2025) |
| 12/31/2024 | 02/13/2025 | 6-K (12/31/2024) |
| 09/30/2024 | 11/14/2024 | 6-K (09/30/2024) |
| 06/30/2024 | 08/13/2024 | 6-K (06/30/2024) |
| 03/31/2024 | 06/27/2024 | 40-F (03/31/2024) |
| 12/31/2023 | 02/13/2024 | 6-K (12/31/2023) |
| 09/30/2023 | 11/13/2023 | 6-K (09/30/2023) |
| 06/30/2023 | 08/11/2023 | 6-K (06/30/2023) |
| 03/31/2023 | 06/30/2023 | 40-F (03/31/2023) |
| 12/31/2022 | 02/13/2023 | 6-K (12/31/2022) |
| 09/30/2022 | 11/15/2022 | 6-K (09/30/2022) |
| 06/30/2022 | 08/08/2022 | 6-K (06/30/2022) |
| 03/31/2022 | 06/30/2022 | 40-F (03/31/2022) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.